+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Variations in Hypothalamic Somatostatin Release and Content during the Estrous Cycle in the Rat

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To investigate the secretory pattern of somatostatin (SS) from the median eminence (ME) in the female rat, as well as estrogenic influence on this secretion, we measured both SS release and hypothalamic content in cycling, 10-day ovariectomized, and ovariectomized rats treated with estradiol for 3 days before. Animals were stereotaxically implanted with a push-pull cannula into the ME, and 10 days later the hypothalamic structure was perfused with artificial cerebrospinal fluid for 120–150 min at a regular flow rate of 17 µl/min. Secretion peaks were observed in the pattern of SS release, whatever the stage of the estrous cycle. The mean amplitude of SS peaks was similar throughout the cycle: 11.7 ± 4.0, 8.6 ± 1.5 and 10.5 ± 1.3 pg at proestrus, estrus and diestrus, respectively, and it was affected neither by ovariectomy (7.4 ± 1.3 pg) nor by estrogen replacement (5.5 ± 1.0 pg). By contrast, mean SS release levels in the proestrus phase were significantly higher than those measured in the other phases: 21.6 ± 2.1 vs. 17.7 ± 1.2 pg/15 min in diestrus (p < 0.05) and vs. 12.0 ± 0.7 pg/15 min in estrus (p < 0.001). Hypothalamic SS content showed variations quite similar to those observed during its release, i.e. with the highest values corresponding to the proestrus phase (1,170.5 ± 224.9 pg/mg of tissue) and to the diestrus (1,156.5 ± 332.1 pg/mg of tissue) and the lowest values in the estrus (511.5 ± 52.9 pg/mg of tissue; p < 0.05 vs. proestrus and diestrus). In addition, the lowest SS content and secretion values were found in ovariectomized animals: 95.5 ± 5.1 pg/mg of tissue (p < 0.001 compared to the values obtained for each stage of the estrous cycle) and 10.0 ± 0.9 pg/15 min (p < 0.001 vs. proestrus and diestrus), respectively. Patterns of SS release and SS hypothalamic content were not modified by estradiol treatment in ovariectomized animals. Our results suggest that (1) whatever the stage of the estrous cycle, SS release from the ME is not uniform and exhibits irregular peaks; (2) mean SS release levels were subjected to gonadal influence; (3) the occurrence of SS peaks seems to be estrogen-independent, and (4) variations in hypothalamic SS content were generally in good agreement with those of neurohormone release.

          Related collections

          Author and article information

          S. Karger AG
          09 April 2008
          : 63
          : 2
          : 181-187
          aLaboratory of Neuroendocrinological Neurobiology, URA 1197 CNRS, University of Montpellier 2, France; bLaboratory of Biochemical Pharmacology, Catholic University of Chile, Santiago, Chile
          126955 Neuroendocrinology 1996;63:181–187
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Somatostatin and Somatoliberin


          Comment on this article